AAPL 171.29 -4.1305% MSFT 429.37 0.9736% GOOG 148.74 -0.628% GOOGL 147.6 -0.7664% AMZN 178.15 0.0% NVDA 914.35 1.1762% META 507.76 0.4431% TSLA 172.82 -1.6168% TSM 139.45 1.9744% LLY 770.26 -0.3364% V 290.37 0.3768% AVGO 1348.0 5.6426% JPM 199.06 1.3905% UNH 491.69 -0.5139% NVO 129.83 -0.4066% WMT 61.45 0.3265% LVMUY 182.95 -1.8193% XOM 113.49 0.4425% LVMHF 913.224 -2.0146% MA 488.64 0.1229%
Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) is a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. The company is majorly involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Why should Investors make an EXIT?
HEPA Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
HEPA's stock price has declined 59.13% in the past twelve months and is currently leaning towards the lower band of its 52-week range of USD 0.862 to USD 3.18. The stock is currently trading below its 50 and 200 DMA levels, and its RSI Index is at 34.15.
Considering the correction in the stock price in the past twelve months, the detrirating financials and macro headwinds, regulatory approval, and associated risks, we recommend to ‘Sell’ the stock at the current price of USD 0.999 as of January 25, 2021, 03:25 PM ET.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
* Depending upon the risk tolerance, investors may consider unwinding their positions in a respective stock once the estimated target price is reached.